Commonly used non-antibiotic medications promote mutation frequency and antimicrobial resistance in Escherichia coli

preprint OA: closed
📄 Open PDF Full text JSON View at publisher
AI-generated deep summary by claude@2026-06, 2026-06-24 · read from full text

The study tested whether commonly used non-antibiotic medications in residential aged care facilities can promote antimicrobial resistance by increasing mutation acquisition in Escherichia coli. E. coli was exposed to gut-relevant concentrations of several non-antibiotic medications, individually and in combinations, together with ciprofloxacin, and mutation frequency and ciprofloxacin resistance were measured; whole genome sequencing was used to identify correlating mutations. Ibuprofen and acetaminophen significantly increased mutation frequency and conferred high ciprofloxacin resistance, with effects further amplified when two NAMs were combined, and sequencing linked these outcomes to mutations in DNA gyrase GyrA, MarR, and AcrR, along with increased acrA transcription of the AcrAB-TolC efflux pump. The paper’s caveat is that it uses an E. coli exposure model rather than assessing clinical outcomes directly, while explicitly framing its findings as a starting point for future work on prescribing practices. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,106 characters · extracted from oa-doi-fallback · click to expand
Abstract Antimicrobial resistance (AMR) poses a global threat to public health. The excessive use of antibiotics significantly contributed to the rise of resistance. Recent evidence suggests that non-antibiotic medications (NAMs) also play a role in antimicrobial resistance development, although this aspect remains less explored and understood. This issue is particularly relevant in residential aged care facilities (RACFs) where both NAMs and antibiotics are frequently used, and AMR is prevalent. We investigated the propensity of NAMs that are commonly used in RACFs and contribute to polypharmacy including non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac, acetaminophen (antipyretic), metformin (glucose-lowering medication), atorvastatin (lipid-lowering agent), tramadol (opioid analgesic), temazepam (hypnotic), and pseudoephedrine (sympathomimetic) to promote bacterial antibiotic resistance by increasing the acquisition of mutations. Escherichia coli was exposed to different NAMs at their gut concentration, combined with ciprofloxacin and the mutation frequency was determined. Additionally, we explored the simultaneous effect of two NAMs as a starting point for studying polypharmacy. Ibuprofen and acetaminophen significantly increased mutation frequency, and conferred high levels of ciprofloxacin resistance, especially when E. coli was exposed to two NAMs. Whole genome sequencing revealed that these changes correlated with mutations in DNA gyrase GyrA, the multiple antibiotic resistance regulator, MarR, and the drug efflux pump expression suppressor, AcrR. Consequently, an increase in transcription of the acrA gene from the AcrAB-TolC drug efflux pump was observed. The combination of two NAMs increased the mutation rate. These multiple mutations caused the higher levels of ciprofloxacin resistance that were observed. Given the risk of polypharmacy to induce AMR, and the results observed in this study, the assessment NAMs in their ability to promote bacterial resistance warrants special attention in future studies into prescribing practices.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-07-02T06:27:13.117293+00:00